RT Journal Article
SR Electronic
T1 A Novel Transfer Learning Model for Predictive Analytics using Incomplete Multimodality Data
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.23.20077412
DO 10.1101/2020.04.23.20077412
A1 Liu, Xiaonan
A1 Chen, Kewei
A1 Wu, Teresa
A1 Weidman, David
A1 Lure, Fleming Y. M.
A1 Li, Jing
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/04/29/2020.04.23.20077412.abstract
AB Multimodality datasets are becoming increasingly common in various domains to provide complementary information for predictive analytics. In health care, diagnostic imaging of different kinds contains complementary information about an organ of interest, which allows for building a predictive model to accurately detect a certain disease. In manufacturing, multi-sensory datasets contain complementary information about the process and product, allowing for more accurate quality assessment. One significant challenge in fusing multimodality data for predictive analytics is that the multiple modalities are not universally available for all samples due to cost and accessibility constraints. This results in a unique data structure called Incomplete Multimodality Dataset (IMD) for which existing statistical models fall short. We propose a novel Incomplete-Multimodality Transfer Learning (IMTL) model that builds a predictive model for each sub-cohort of samples with the same missing modality pattern, and meanwhile couples the model estimation processes for different sub-cohorts to allow for transfer learning. We develop an Expectation-Maximization (EM) algorithm to estimate the parameters of IMTL and further extend it to a collaborative learning paradigm that is specifically valuable for patient privacy preservation in health care applications of the IMTL. We prove two advantageous properties of IMTL: the ability for out-of-sample prediction and a theoretical guarantee for a larger Fisher information compared with models without transfer learning. IMTL is applied to diagnosis and prognosis of the Alzheimer’s Disease (AD) at an early stage of the disease called Mild Cognitive Impairment (MCI) using incomplete multimodality imaging data. IMTL achieves higher accuracy than competing methods without transfer learning.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported in part by 1R41AG053149-01A1. The funding sources did not play a role in study design, the collection, analysis and interpretation of data, writing of the report; or in the decision to submit the article for publication. Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in the preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf